Defunct Company
Total Trials
10
As Lead Sponsor
As Collaborator
0
Total Enrollment
745
NCT02190747
An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects
Phase: Phase 2
Role: Lead Sponsor
Start: Jul 14, 2014
Completion: May 23, 2016
NCT02279095
An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
Start: Oct 9, 2014
Completion: Sep 20, 2022
NCT02322255
A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)
Phase: N/A
Start: Dec 18, 2014
Completion: Apr 9, 2020
NCT04829786
Study to Compare the Pharmacokinetics, Safety, and Tolerability Following Administration of Palovarotene in Healthy Japanese and Non-Asian Subjects
Phase: Phase 1
Start: Sep 1, 2015
Completion: Oct 23, 2015
NCT02521792
In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects
Start: Dec 7, 2015
Completion: Aug 4, 2016
NCT03312634
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Phase: Phase 3
Start: Nov 30, 2017
Completion: Sep 7, 2022
NCT03442985
An Efficacy and Safety Study of Palovarotene for the Treatment of MO
Start: Mar 22, 2018
Completion: Oct 30, 2020
NCT04762355
Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects
Start: Aug 30, 2018
Completion: Jan 3, 2019
NCT04829773
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects
Start: Jan 3, 2019
Completion: Mar 29, 2019
NCT05039515
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Start: Dec 1, 2021
Completion: Mar 30, 2029